Repligen vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Repligen Corporation (RGEN)

Q3 202630 Jun – 28 Jul 2026

▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.
This is the biggest new event driving RGEN's price, showing a major growth move.
Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.
This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.
Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.
It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.
Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.
This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

July 202630 Jun – 28 Jul 2026

▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.
This is the biggest new event driving RGEN's price, showing a major growth move.
Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.
This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.
Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.
It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.
Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.
This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Latest30 Jun – 28 Jul 2026

▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.
This is the biggest new event driving RGEN's price, showing a major growth move.
Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.
This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.
Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.
It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.
Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.
This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Agilent Technologies Inc (A)

Q3 20269 Jul – 26 Aug 2026

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.
New product and guidance signal future growth, a key driver for the stock.
FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.
Regulatory wins open new markets and deepen partnerships, directly boosting future sales.
Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.
Guidance raise and China recovery are the biggest new fundamental drivers for the stock.
Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.
Provides a fair counterweight to the positive news, showing what could hold the stock back.

August 20269 Jul – 26 Aug 2026

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.
New product and guidance signal future growth, a key driver for the stock.
FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.
Regulatory wins open new markets and deepen partnerships, directly boosting future sales.
Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.
Guidance raise and China recovery are the biggest new fundamental drivers for the stock.
Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.
Provides a fair counterweight to the positive news, showing what could hold the stock back.

Latest9 Jul – 26 Aug 2026

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.
New product and guidance signal future growth, a key driver for the stock.
FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.
Regulatory wins open new markets and deepen partnerships, directly boosting future sales.
Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.
Guidance raise and China recovery are the biggest new fundamental drivers for the stock.
Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.
Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 202620 Jun – 26 Jun 2026

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.
This is the core financial result that directly drives the stock and shows the company's health.
Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.
This is a major strategic move that directly affects future growth and profitability.
China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.
It shows Agilent investing in future technologies and markets, which can drive growth.
Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.
It highlights a favorable industry trend that supports Agilent's revenue growth.

June 202620 Jun – 26 Jun 2026

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.
This is the core financial result that directly drives the stock and shows the company's health.
Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.
This is a major strategic move that directly affects future growth and profitability.
China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.
It shows Agilent investing in future technologies and markets, which can drive growth.
Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.
It highlights a favorable industry trend that supports Agilent's revenue growth.

20 Jun – 26 Jun 2026

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.
This is the core financial result that directly drives the stock and shows the company's health.
Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.
This is a major strategic move that directly affects future growth and profitability.
China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.
It shows Agilent investing in future technologies and markets, which can drive growth.
Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.
It highlights a favorable industry trend that supports Agilent's revenue growth.